Targeting Karyotypic Complexity and Chromosomal Instability of Cancer Cells
Multiple karyotypic abnormalities and chromosomal instability are characteristic features of many cancers that are relatively resistant to chemotherapeutic agents currently used in the clinic. These same features represent potentially targetable “states” that are essentially tumor specific. The assessment of the chromosomal state of a cancer cell population may provide a guide for the selection or development of drugs active against aggressive and intractable cancers.
Keywords: 5-fluorouracil; Alkylators; Aneuploidy; Anthracyclines; Anticancer drugs; Anticancer therapy; Antifolates; CENP-E heterozygous; CIN; Cancer; Cancer progression; Cancer spectrum; Centrosomes; Chemotherpeutic agents; Chromatid cohesion; Chromosomal instability; Chromosomal instability phenotype; Chromosome missegregating; Drosophila; ECM-receptor interaction pathways; GI50 data vectors; Gemcitabine; Griseofulvin; Heterogeneity; JAK-STAT signaling pathways; Karyotic abnormalities; Kinetochore; Mercapto-3H quinazolines; Microsatellite instability; NCI-60; Neoplasia; Saccharomyces cerevisiae; Schizosaccharomyces pombe; Topoisomerase agents; Trisomies; Tumorigenesis
Document Type: Research Article
Publication date: 01 October 2010
- Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content